Keynote Lecture


Date: 4th December 2022
Time: 14:30-15:15
Moderators: Dr. Gary SH CHEUNG, Dr. Vincent NH LUK

My 20-year journey of TAVI


Consultant Cardiologist
Rigshospitalet, Copenhagen
Professor of Cardiology
University of Copenhagen

Based on the pioneering works by Henning Rud Andersen, Alain Cribier performed the first in human transcatheter aortic valve implantation (TAVI) in 2002. Subsequently, TAVI has led to a paradigm shift in the treatment of elderly patients with severe aortic stenosis. Several randomized clinical trials have demonstrated that safety of TAVI is at least non-inferior to SAVR in these patients regardless their risk profiles. This in combination with optimized pre-procedural planning, procedural steps, and patient pathway has led to expanding indications for TAVI. Furthermore, it is foreseen that also patients with e.g., longer life-expectancy, asymptomatic severe aortic stenosis, symptomatic moderate aortic stenosis, or pure aortic regurgitation may potentially be offered TAVI soon. However, treating such patients with TAVI requires further device developments as well as procedural refinements to reduce the risk of e.g., new conduction abnormalities, paravalvular leakage, and impaired access to the coronary arteries after TAVI. Furthermore, strategies for life-time management of younger patients need to consider both durability of the bioprosthetic aortic valves and the possibilities for re-valving when the valve eventually fails.


Organized by:
Supported by:

Copyright © 2022 APCASH 2022 | All rights reserved.